Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Window-of-opportunity platform trial of olaparib, cediranib, and durvalumab in resectable renal cell cancer
2018-003056-21Phase 2Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Aug 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib, cediranib and durvalumab in renal cell carcinoma (RCC) and kidney cancer (4 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Reduction in Ktrans on mpMRI, Proof-of-mechanism and 1 more. Status: unknown.
02
Drugs
olaparibcediranibdurvalumab
03
Conditions
renal cell carcinoma (RCC)kidney cancer
Beyond the preview
Go deeper on 2018-003056-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003056-21.